Agilent Files 8-K: Routine Administrative Update

TL;DR

**Agilent's 8-K is a routine administrative filing with no new material news.**

AI Summary

Agilent Technologies, Inc. filed an 8-K on January 5, 2024, to report a current event. This filing primarily serves to update administrative details, such as confirming its status as a Delaware corporation with its principal executive offices at 5301 Stevens Creek Boulevard, Santa Clara, CA 95051. For investors, this filing is largely procedural and does not contain new financial or operational information that would directly impact the stock's valuation or future prospects, indicating business as usual.

Why It Matters

This filing is a standard administrative update, confirming basic company information. It signals no immediate changes to Agilent's operations or financial health, which means current investors shouldn't expect any direct stock price movement from this specific report.

Risk Assessment

Risk Level: low — This 8-K filing is purely administrative and does not disclose any new risks or material events that would impact the company's financial standing or operations.

Analyst Insight

A smart investor would recognize this 8-K as a routine administrative update, not containing any new material information that would warrant immediate action. It's a 'no news is good news' scenario, suggesting stability rather than a catalyst for price movement.

Key Numbers

• January 5, 2024 — Date of Report (This is the date of the earliest event reported in the filing.)
• 001-15405 — Commission File Number (This is Agilent's unique identifier with the SEC.)
• 77-0518772 — IRS Employer Identification No. (This is Agilent's tax identification number.)
• $0.01 — Par Value per share (This is the stated par value for Agilent's Common Stock.)

Key Players & Entities

• AGILENT TECHNOLOGIES, INC. (company) — the registrant filing the 8-K
• Delaware (company) — state of incorporation for Agilent Technologies, Inc.
• 5301 Stevens Creek Boulevard, Santa Clara, CA 95051 (company) — principal executive offices of Agilent Technologies, Inc.
• January 5, 2024 (date) — date of earliest event reported and filing date
• 001-15405 (dollar_amount) — Commission File Number
• 77-0518772 (dollar_amount) — IRS Employer Identification No.
• (800) 227-9770 (dollar_amount) — Registrant's telephone number
• COMMON STOCK, $0.01 PAR VALUE (company) — title of class of securities registered
• A (company) — trading symbol for Agilent Technologies, Inc.
• New York Stock Exchange (company) — exchange on which securities are registered

FAQ

Key Financial Figures

• $0.01 — ANGE ON WHICH REGISTERED COMMON STOCK, $0.01 PAR VALUE A New York Stock Exchange I

Filing Documents

• a-20240105.htm (8-K) — 36KB
• exhibit991-segmentrecast.htm (EX-99.1) — 194KB
• 0001090872-24-000003.txt ( ) — 365KB
• a-20240105.xsd (EX-101.SCH) — 2KB
• a-20240105_lab.xml (EX-101.LAB) — 24KB
• a-20240105_pre.xml (EX-101.PRE) — 13KB
• a-20240105_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On December 20, 2023, we issued a press release announcing that we had moved our Cell Analysis Division into the Diagnostics and Genomics Group (DGG) business segment from the Life Sciences and Applied Markets Group (LSAG) business segment to further strengthen growth opportunities for both organizations. Following this reorganization, we will continue to have three business segments (LSAG, DGG and Agilent CrossLab), each of which will continue to comprise a reportable segment. We are furnishing this Current Report on Form 8-K to present selected segment information that reflect changes in our reportable segments related to the changes in our organizational structure. Beginning with the quarter ending January 31, 2024, our financial statements will reflect the new reporting structure with prior periods recast accordingly. The information contained in this report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section 18. Furthermore, the information contained in this report shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits The following is furnished as an exhibit to this report and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended: Exhibit No. Description 99.1 Selected segment information for the fiscal quarters ended January 31, 2021, 2022 and 2023, April 30, 2021, 2022 and 2023, July 31, 2021, 2022 and 2023 and October 31, 2021, 2022 and 2023 and fiscal years ended October 31, 2021, 2022 and 2023. 104 Cover page interactive data file (embedded within the Inline XBRL document) 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AGILENT TECHNOLOGIES, INC. By: /s/ P. Diana Chiu Name: P. Diana Chiu Title: Vice President, Interim General Counsel and Secretary Date: January 5, 2024 3

View Full Filing

View this 8-K filing on SEC EDGAR